Report Thumbnail
Product Code IW091281444HB5
Published Date 2021/8/2
English150 PagesAsia Pacific

ASIA-PACIFIC COUGH SYRUP MARKET FORECAST 2021-2028Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code IW091281444HB5◆The Aug 2025 edition is also likely available. We will check with the publisher immediately.
Published Date 2021/8/2
English 150 PagesAsia Pacific

ASIA-PACIFIC COUGH SYRUP MARKET FORECAST 2021-2028Pharmaceutical_LifeSciense Market



Abstract


Summary

KEY FINDINGS The Asia-Pacific cough syrup market is set to progress with a CAGR of 3.29% across the forecasting years of 2021 to 2028. The increasing rising rates of air pollution and greenhouse farming, the influence of diverse social, economic, and environmental factors on lung health, and the rising geriatric population are among the top drivers set to facilitate the region’s market growth. MARKET INSIGHTS The Asia-Pacific cough syrup market growth assessment includes the detailed study of Vietnam, Thailand, India, Indonesia, Australia & New Zealand, South Korea, Japan, China, and the rest of the Asia-Pacific. Chronic cough is highly prevalent in South Korea and affects nearly 3% of Korean adults. Besides, the condition also has a substantial influence on the quality of life. As one of the most rapidly aging nations, South Korea harbored nearly 1.7 million people aged 65 years and over in 2020. Furthermore, the geriatric population, in addition to the surging air pollution, are the main challenges faced, especially from an epidemiological perspective. On the other hand, air pollution in Indonesia leads to severe diseases such as bronchial asthma, acute respiratory infection, lung cancer, bronchitis, and others. Moreover, problems associated with air pollution have also resulted in approximately 50% of morbidity across the country. Therefore, the abovementioned factors are anticipated to play a vital role in propelling the cough syrup market growth in the Asia-Pacific during the forecast period. COMPETITIVE INSIGHTS Leading companies operating in the market are Cipla Limited, The Himalaya Drug Company, Takeda Pharmaceutical Company Limited, Sinopharm Group Co Ltd, etc. Our report offerings include: • Explore key findings of the overall market • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges) • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions • Market Segmentation cater to a thorough assessment of key segments with their market estimations • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share • Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc. • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc. • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Table of Contents

  • 1 RESEARCH SCOPE & METHODOLOGY

    • 1.1 STUDY OBJECTIVES
    • 1.2 SCOPE OF STUDY
    • 1.3 METHODOLOGY
    • 1.4 ASSUMPTIONS & LIMITATIONS
  • 2 EXECUTIVE SUMMARY

    • 2.1 MARKET SIZE & ESTIMATES
    • 2.2 MARKET OVERVIEW
  • 3 MARKET DYNAMICS

    • 3.1 KEY DRIVERS
      • 3.1.1 RISING GERIATRIC POPULATION
      • 3.1.2 INCREASE IN CHRONIC RESPIRATORY DISEASES
    • 3.2 KEY RESTRAINTS
      • 3.2.1 OVERDOSE RISKS ASSOCIATED WITH COUGH SYRUP
      • 3.2.2 GOVERNMENT REGULATIONS AND RESTRICTIONS
  • 4 KEY ANALYTICS

    • 4.1 IMPACT OF COVID-19 ON COUGH SYRUP MARKET
    • 4.2 KEY MARKET TRENDS
    • 4.3 PORTER’S FIVE FORCES ANALYSIS
      • 4.3.1 BUYERS POWER
      • 4.3.2 SUPPLIERS POWER
      • 4.3.3 SUBSTITUTION
      • 4.3.4 NEW ENTRANTS
      • 4.3.5 INDUSTRY RIVALRY
    • 4.4 OPPORTUNITY MATRIX
    • 4.5 VENDOR LANDSCAPE
  • 5 MARKET BY PRODUCT TYPE

    • 5.1 COUGH SUPPRESSANTS/ANTITUSSIVES
    • 5.2 COMBINATION MEDICATIONS
    • 5.3 EXPECTORANTS
  • 6 MARKET BY AGE GROUP

    • 6.1 ADULT
    • 6.2 PEDIATRIC
  • 7 MARKET BY DISTRIBUTION CHANNELS

    • 7.1 RETAIL PHARMACY
    • 7.2 HOSPITAL PHARMACY
    • 7.3 ONLINE PHARMACY
  • 8 GEOGRAPHICAL ANALYSIS

    • 8.1 ASIA-PACIFIC
      • 8.1.1 MARKET SIZE & ESTIMATES
      • 8.1.2 KEY DRIVERS
      • 8.1.3 KEY CHALLENGES
      • 8.1.4 KEY PLAYERS
      • 8.1.5 COUNTRY ANALYSIS
        • 8.1.5.1 CHINA
        • 8.1.5.2 JAPAN
        • 8.1.5.3 INDIA
        • 8.1.5.4 SOUTH KOREA
        • 8.1.5.5 INDONESIA
        • 8.1.5.6 THAILAND
        • 8.1.5.7 VIETNAM
        • 8.1.5.8 AUSTRALIA & NEW ZEALAND
        • 8.1.5.9 REST OF ASIA-PACIFIC
  • 9 COMPETITIVE LANDSCAPE

    • 9.1 KEY STRATEGIC DEVELOPMENTS
      • 9.1.1 MERGERS & ACQUISITIONS
      • 9.1.2 PARTNERSHIPS & AGREEMENTS
    • 9.2 COMPANY PROFILES
      • 9.2.1 ABBOTT LABORATORIES
      • 9.2.2 ACELLA PHARMACEUTICALS LLC
      • 9.2.3 ASTRAZENECA PLC
      • 9.2.4 CIPLA LIMITED
      • 9.2.5 DABUR INDIA LTD
      • 9.2.6 GLAXOSMITHKLINE PLC
      • 9.2.7 GLENMARK PHARMACEUTICAL LIMITED
      • 9.2.8 JOHNSON & JOHNSON
      • 9.2.9 MERCK KGAA
      • 9.2.10 NOVARTIS INTERNATIONAL AG
      • 9.2.11 PFIZER INC
      • 9.2.12 PROCTOR & GAMBLE CO (P&G)
      • 9.2.13 RECKITT BENCKISER GROUP PLC
      • 9.2.14 SANOFI SA
      • 9.2.15 THE HIMALAYA DRUG COMPANY
USD 1,600 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.